Pfizer
Pfizer
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and
safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with
heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF
trial.Zannad et al
European Journal of Heart Failure. 2015 Jul;17(7):735-42. Epub 2015 Apr 27.
DOI: 10.1002/ejhf.266Auftragsnummer: 200801
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and
safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with
heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF
trial.Zannad et al
European Journal of Heart Failure. 2015 Jul;17(7):735-42. Epub 2015 Apr 27.
DOI: 10.1002/ejhf.266Auftragsnummer: 200801
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and
safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with
heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF
trial.Zannad et al
European Journal of Heart Failure. 2015 Jul;17(7):735-42. Epub 2015 Apr 27.
DOI: 10.1002/ejhf.266Auftragsnummer: 200801
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and
safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with
heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF
trial.Zannad et al
European Journal of Heart Failure. 2015 Jul;17(7):735-42. Epub 2015 Apr 27.
DOI: 10.1002/ejhf.266Auftragsnummer: 200801
direct
mail
de
en
- Generieren
Ihr generierter Kurzlink
https://weblink.reprintsonline.de/mail-9cb660c323df40b98230ebfdb9235e330e17506e
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Australia
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Austria
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
Solomon et al.
JCO 2018, doi: 10.1200/JCO.2017.77.4794
Auftragsnummer: 200833 Austria
direct
mail
de
en
- Generieren
-
Login:
-
(Logout)
| mwo-reprint@mwoffice.de | +49 (0)89 / 96086-0 |
